Health News Releases

  • Today April 10
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatmen
November 20, 2017 10:55
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-l
November 17, 2017 09:55
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in pre
November 16, 2017 18:20
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for th
November 15, 2017 18:35
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy
Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions 2017 in Anaheim, California. RE-DUAL PCI™ investigated different treatment approaches i
November 15, 2017 13:20
Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib[1]
AstraZeneca today announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone
November 15, 2017 13:10
New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery
Boehringer Ingelheim announced results from two sub-analyses of the phase III RE-VERSE AD™ study.[1,2] The sub-analyses evaluated the safety and efficacy of idarucizumab (marketed as Praxbind®) in rev
November 14, 2017 18:05
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These res
November 14, 2017 10:05
Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases
Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases i
November 10, 2017 10:09
Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced that more than 1,300 employees are rallying together in support of community service initiatives focused on health, wellness, and education as par
SELVAS AI will receive CES 2018 Innovation Award for its deep learning based AI disease prediction s
November 10, 2017 09:19
SELVAS AI to Receive CES 2018 Innovation Award for Disease Prediction Solution Using Artificial Intelligence
SELVAS AI, an artificial intelligence company, will receive CES 2018 Innovation Award for its AI disease prediction solution “Selvy Checkup” at the CES (Consumer Electronics Show) 2018, one of the lar
November 09, 2017 18:20
Patient Safety Movement Foundation to Co-Convene World Summit with the European Society of Anaesthesiology
The Patient Safety Movement Foundation announced today that the European Society of Anaesthesiology (ESA) will co-convene the upcoming 6th Annual World Patient Safety, Science & Technology Summit, hel
November 09, 2017 17:15
Patient Safety Movement Foundation and Dubai Healthcare City Authority Launch First Patient Safety Movement in the Middle East
The Patient Safety Movement Foundation (PSMF) is pleased to announce the first patient safety movement of its kind in the Middle East that aims to eliminate preventable deaths. The movement, which is
November 09, 2017 10:10
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development
November 08, 2017 13:50
Progenity Announces Closing of $125 Million Financing for Prenatal-Women’s Health Genetics and Gastrointestinal/Inflammatory Bowel Disease Precision Medicine
Progenity Inc., a private biotechnology company, announced today the completion of a privately placed $125 million Series B financing comprising equity and debt. The financing was led by a fund manage
November 07, 2017 17:00
Takeda to Showcase Data That May Reshape the Future of Blood Cancer Treatments During 59th American Society of Hematology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 11 company-sponsored abstracts at the 59th American Society of Hematology (ASH) Annual Meeting taking
November 07, 2017 16:00
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
Takeda Pharmaceutical Company Limited (TSE: 4502), (“Takeda”) today announced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated tetravalent dengu
November 07, 2017 15:20
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed th
November 03, 2017 11:55
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreem
November 02, 2017 16:45
Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)
Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced positive top line results from a clinical study evaluating the efficacy and safety of AltemiaTM, an oral soft gelatin dosage form, in pedi
November 02, 2017 13:25
Takeda Reports First Half FY2017 Results
Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.7% led by Takeda's Growth Drivers · Underlying Revenue grew +6.7% with solid performances across all regions (U
October 31, 2017 13:40
GRAMINEX L.L.C. expands its partnership with IDIPharma after clinical study publication.
Graminex® LLC, producer of Non-Solvent Graminex® Flower Pollen Extracts™, is pleased to announce the expansion of its partnership with IDIPharma. After completion and publication of clinical studies s
October 31, 2017 09:55
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncolo
October 30, 2017 10:00
Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III RADIANCE™ Part B trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phos
October 30, 2017 09:55
Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1
October 26, 2017 09:15
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) has shown to be both highly effective and well-tolerated in
25 per page50 per page75 per page100 per page